Sponsor · clinical trials

LETI Pharma clinical trials

Source: the EU Clinical Trials Information System (CTIS) — current trials in our EU (CTIS) register with LETI Pharma as lead sponsor. Synced 10 Nov 2026

3Current trials

0Recruiting now

3Drugs in these trials

1Trial register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

LETI Pharma is the lead sponsor of 3 current clinical trials in our EU (CTIS) register. The drugs named most often in its trials are Desloratadine, Montelukast and Salbutamol.

LETI Pharma in the EU trials register (CTIS)

3 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with LETI Pharma as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
Phase III, double blind, placebo controlled, clinical trial to evaluate the efficacy and safety of Depigoid Olea europaea (1000 DPP/mL), a depigmented polymerised allergen extract of olive pollen, compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis with or without asthma due to olive pollen allergy. 2026-525840-13-00 · CTIS ↗ · Immune System Diseases	Phase 3	Authorised	Portugal, Spain
Clinical trial to evaluate the efficacy and safety of Depigoid Grass-Mix at 1000 DPP/mL and Depigoid FORTE Grass-Mix at 3000 DPP/mL compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma due to clinically relevant sensitisation to grass pollen. 2025-521736-10-00 · CTIS ↗ · Immune System Diseases	Phase 3	Ongoing	Portugal, Spain
A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma 2025-521230-29-00 · CTIS ↗ · Immune System Diseases Drugs: Desloratadine, Montelukast, Salbutamol	Phase 3	Ongoing	Spain, Portugal

Drugs in LETI Pharma trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Desloratadine1 Montelukast1 Salbutamol1

By trial register

Register	Trials	Recruiting
EU register (CTIS)	3	—

A trial with sites in more than one country appears in each of those registers.

Questions about LETI Pharma trials

How many clinical trials does LETI Pharma sponsor?

LETI Pharma is the lead sponsor of 3 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Which drugs is LETI Pharma testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Desloratadine (1), Montelukast (1) and Salbutamol (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.